Jefferies Group Increases Protalix BioTherapeutics Price Target to $5.50 (PLX)
Equities research analysts at Jefferies Group boosted their target price on shares of Protalix BioTherapeutics (NYSE:PLX) from $5.00 to $5.50 in a research note issued to investors on Tuesday, American Banking News.com reports. Jefferies Group’s price objective points to a potential upside of 18.53% from the stock’s previous close.
Shares of Protalix BioTherapeutics (NYSE:PLX) traded up 0.22% on Tuesday, hitting $4.65. The stock had a trading volume of 101,194 shares. Protalix BioTherapeutics has a 52 week low of $3.70 and a 52 week high of $6.73. The stock’s 50-day moving average is $3.97 and its 200-day moving average is $4.64. The company’s market cap is $429.8 million.
A number of other firms have also recently commented on PLX. Analysts at Zacks upgraded shares of Protalix BioTherapeutics from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday, December 25th. They now have a $4.70 price target on the stock. Analysts at JPMorgan Chase & Co. initiated coverage on shares of Protalix BioTherapeutics in a research note to investors on Monday, October 21st. They set an “overweight” rating on the stock.
Protalix BioTherapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.